Kirchheimer J C, Pflüger H, Hienert G, Binder B R
Int J Cancer. 1985 Jun 15;35(6):737-41. doi: 10.1002/ijc.2910350607.
Eighteen patients with renal-cell carcinoma have been investigated in an attempt to elucidate the ratio of active urokinase enzyme to urokinase antigen in the tumor and adjacent normal kidney. The tumor itself exhibited a significantly increased total fibrinolytic activity, an increase in the relative contribution of anti-urokinase IgG-inhibitable plasminogen activator activity and increased levels of urokinase antigen when compared to normal renal tissue. In tumor-adjacent tissue total fibrinolytic activity was also, but not significantly, increased, this increase being completely due to tissue-type plasminogen activator. Correlation of active urokinase-type plasminogen activator with urokinase antigen revealed that in tumor tissue the enzyme was present to more than 70% in its active form whereas in tumor-adjacent tissue and normal renal tissue only half of the enzyme appeared to be active. No correlation was obtained between urokinase antigen present in one of the 3 tissues investigated and plasma urokinase antigen.
对18例肾细胞癌患者进行了研究,以阐明肿瘤及邻近正常肾脏中活性尿激酶酶与尿激酶抗原的比例。与正常肾组织相比,肿瘤本身的总纤溶活性显著增加,抗尿激酶IgG抑制的纤溶酶原激活剂活性的相对贡献增加,尿激酶抗原水平升高。在肿瘤邻近组织中,总纤溶活性也有所增加,但不显著,这种增加完全归因于组织型纤溶酶原激活剂。活性尿激酶型纤溶酶原激活剂与尿激酶抗原的相关性显示,在肿瘤组织中,该酶以超过70%的活性形式存在,而在肿瘤邻近组织和正常肾组织中,只有一半的酶似乎具有活性。在所研究的3种组织之一中存在的尿激酶抗原与血浆尿激酶抗原之间未发现相关性。